Ketamine: all studies (page 446) - The Consciousness Library

MK-801, a proposed noncompetitive antagonist of excitatory amino acid neurotransmission, produces phencyclidine-like behavioral effects in pigeons, rats and rhesus monkeys.

Journal of Pharmacology and Experimental Therapeutics June 1, 1988 Wouter Koek, James H Woods, Gail Winger

The behavioral effects of MK-801 [(+)-5-methyl-10,11-dihydroxy-5H-dibenzo(a,d)cyclohepten-5,10-imin e], a proposed noncompetitive N-methyl-D-aspartate (NMDA) antagonist, were compared to those of phencyclidine (PCP). In pigeons, MK-801 produced PCP-like catalepsy (i.e., loss of righting without eye closure and without muscle relaxation) and PCP-like discriminative stimulus effects. In rats,...

DOI: 10.1016/s0022-3565(25)24082-4

'Designer drugs'. A problem in clinical toxicology.

Medical toxicology and adverse drug experience 1988 J F Buchanan, C R Brown

'Designer drugs' are substances intended for recreational use which are derivatives of approved drugs so as to circumvent existing legal restrictions. The term as popularised by the lay press lacks precision. Contrary to the popular belief that 'designer drugs' are original creations, the majority of these agents are 'borrowed' from legitimate pharmaceutical research. They merely represent the...

DOI: 10.1007/bf03259928 Full text

Enantiomeric and diastereomeric dioxadrols: behavioral, biochemical and chemical determination of the configuration necessary for phencyclidine-like properties.

Journal of Pharmacology and Experimental Therapeutics October 1, 1987 A. E. Jacobson, E. A. Harrison, M. V. Mattson et al.

Dioxadrol exists in four isomeric forms. alpha-(+)-Dioxadrol (dexoxadrol) showed phencyclidine (PCP)-like activity in rhesus monkeys trained to discriminate s.c. administration of ketamine, but neither alpha-(-)-dioxadrol (levoxadrol) nor beta-(+/-)-dioxadrol showed such activity. In addition, response-contingent i.v. dexoxadrol maintained higher rates of responding than either levoxadrol or...

DOI: 10.1016/s0022-3565(25)39206-2

Metaphit, a proposed phencyclidine receptor acylator: phencyclidine-like behavioral effects and evidence of absence of antagonist activity in pigeons and in rhesus monkeys.

Journal of Pharmacology and Experimental Therapeutics May 1, 1986 Wouter Koek, James H Woods, A. E. Jacobson et al.

Metaphit, a derivative of phencyclidine (PCP), binds irreversibly to PCP sites and appears to act as an antagonist of PCP under some conditions and as a PCP-like agonist under other conditions. To describe further these conditions, the authors investigated the behavioral effects of metaphit by using different routes of administration, behavioral procedures and species. In pigeons, metaphit...

DOI: 10.1016/s0022-3565(25)24934-5

Action of hallucinogens on raphe-evoked dorsal root potentials (DRPs) in the cat.

Pharmacology, Biochemistry, and Behavior February 1, 1986 A A Larson, E G Anderson

The dorsal root potential (DRP) evoked by stimulation of the inferior central nucleus (ICN) of the cat is affected by administration of a variety of hallucinogenic agents. It has been previously shown that a single low dose of LSD is unique in that it potentiates this DRP, while injections of 5-methoxy-N,N- dimethyltryptamine (5-MeODMT), ketamine or phencyclidine (PCP) inhibit its production....

DOI: 10.1016/0091-3057(86)90364-3 Full text

Antagonism of N-methyl-D-aspartate-induced transmitter release in the rat striatum by phencyclidine-like drugs and its relationship to turning behavior.

Journal of Pharmacology and Experimental Therapeutics October 1, 1985 L. Snell, K. Johnson

Representatives from several chemical classes known to share behavioral properties with phencyclidine [(1-phenylcyclohexyl)piperidine] (PCP) have been shown to antagonize the excitatory effects of N-methylaspartate on spinal neurons selectively. This study compared the abilities of several of these PCP-like drugs to inhibit N-methyl-D-aspartate (NMDA)-stimulated efflux of acetylcholine in rat...

DOI: 10.1016/s0022-3565(25)23841-1

A comparison between classes of drugs having phencyclidine-like behavioral properties on dopamine efflux in vitro and dopamine metabolism in vivo.

Journal of Pharmacology and Experimental Therapeutics November 1, 1984 L. Snell, Z. Mueller, R. Gannon et al.

Phencyclidine [(l-phenylcyclohexyl) piperidine] (PCP) is known to increase the basal efflux of striatal dopamine (DA) in vitro and to enhance haloperidol (HAL)-induced striatal DA metabolism in vivo. This study compared these activities of PCP to several representatives of the arylcyloalkylamine, benzomorphan and substituted dioxolane classes whose behavioral similarities to PCP have been well...

DOI: 10.1016/s0022-3565(25)21585-3

Phencyclidine-like discriminative effects of opioids in the rat.

Journal of Pharmacology and Experimental Therapeutics September 1, 1980 S. Holtzman

Possible commonalities in the discriminative stimulus properties of phencyclidine (PCP) and opioids were investigated in rats trained to discriminate between i.p. injections of saline and 2.0 mg/kg of PCP in a two-choice discrete-trial avoidance paradigm. Behavior was considered to be under stimulus control when a rat reliably completed at least 18 trials of a 20-trial session on the...

DOI: 10.1016/s0022-3565(25)32225-1

The Paradox of Phencyclidine (PCP) Abuse

Annals of Internal Medicine March 1, 1979 R. C. Stillman, Robert C. Petersen 38 citations

Editorials1 March 1979The Paradox of Phencyclidine (PCP) AbuseRICHARD STILLMAN, M.D., ROBERT C. PETERSEN, PH.D.RICHARD STILLMAN, M.D.Search for more papers by this author, ROBERT C. PETERSEN, PH.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-90-3-428 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack...

DOI: 10.7326/0003-4819-90-3-428 Phencyclidine

Characteristics of Ongoing Clinical Trials of Psychogenic Substances for Psychiatric Disorders.

Journal of Clinical Psychopharmacology John L. Havlik, Sayana Isaac, Pralahad Raman et al.

With a rapid rise in clinical trials investigating psychogenic substances, the field faces considerable concerns regarding transparency and conflicts of interest. This study aims to systematically characterize ongoing NIH-registered clinical trials investigating psychogenic substances for psychiatric disorders as of late 2024, including research protocols, institutional settings, and funding...

DOI: 10.1097/jcp.0000000000002095 Full text Clinical trials Conflicts of interest Pharmacotherapy Psychedelics

Research